Company Overview
Tenon Medical, Inc., a medical device company, engages in the development of implant for the treatment of severe lower back pain in the United States. The company offers Catamaran SI-Joint Fusion System, an invasive inferior-posterior approach to the sacroiliac joint (SI Joint) using a titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. It also provides Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, transfixing the SI Joint along its longitudinal axis. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.
Why Investors Should Care
Revenue has grown at a 78.7% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $3.94M (+20.4% YoY); net profit $-12.56M.
- Trailing 12 Months Year-on-year growth — revenue +126.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 78.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 78.71% |
| 1 Year: | 126.80% |
Stock Price Performance
| 1 Year: | +101.20% |
| 6 Months: | -87.82% |
| 3 Months: | -84.00% |
| 1 Month: | -26.72% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)35.63 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 78.7% over 5 years.
CONS
- Trading 92.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TNON Tenon Medical, Inc. PHARMA | 3.36 | -0.08 | $2.24M | 0.00% | - | - | 78.71% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.00K | 22.00K | 70.00K | 71.00K | 135.00K | 208.00K | 433.00K | 743.00K | 944.00K | 719.00K | 901.00K | 887.00K | - | 726.00K | 564.00K | 1.17M | 1.48M | 1.38M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 403.00K | 319.00K | 400.00K | 464.00K | 434.00K |
| Gross Profit | 4.00K | 13.00K | 52.00K | -204.00K | -136.00K | -94.00K | -47.00K | 194.00K | 535.00K | 470.00K | 470.00K | 418.00K | - | 323.00K | 245.00K | 773.00K | 1.02M | 945.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.00M | 3.10M | 4.17M | 3.88M | 4.22M |
| Operating Income | -189.00K | -1.61M | -2.10M | -2.08M | -5.46M | -3.26M | -4.89M | -4.32M | -3.38M | -3.51M | -3.87M | -3.21M | - | -3.68M | -2.86M | -3.39M | -2.87M | -3.28M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.51M | -2.65M | -3.19M | -2.67M | -3.15M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 176.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.62M | -2.77M | -3.34M | -2.83M | -3.48M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -200.00K | -1.67M | -2.34M | -2.35M | -5.49M | -3.17M | -4.83M | -4.29M | -3.33M | -3.58M | -3.83M | -3.18M | - | -3.62M | -2.77M | -3.34M | -2.83M | -3.48M |
| Diluted EPS | - | -2.01 | -2.55 | -2.38 | -0.65 | -2.82 | -4.30 | -3.28 | -11.69 | -10.02 | -8.16 | -3.63 | - | -1.01 | -0.36 | -0.40 | - | -0.31 |
| R&D Expense | 87.00K | 237.00K | 601.00K | 562.00K | 657.00K | 797.00K | 834.00K | 901.00K | 737.00K | 669.00K | 708.00K | 657.00K | - | 691.00K | 503.00K | 428.00K | - | 662.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 691.00K | 2.93M | 3.28M | 3.94M |
| Cost of Revenue | - | 1.33M | 1.69M | 1.57M | 1.59M |
| Gross Profit | - | -641.00K | 1.24M | 1.71M | 2.36M |
| Operating Expenses | - | 18.08M | 16.97M | 15.48M | 15.15M |
| Operating Income | - | -18.73M | -15.73M | -13.77M | -12.79M |
| EBITDA | - | -18.27M | -15.13M | -12.98M | -12.03M |
| Interest Expense | - | 354.00K | 21.00K | 34.00K | 0 |
| Pretax Income | - | -18.92M | -15.58M | -13.67M | -12.56M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -18.92M | -15.58M | -13.67M | -12.56M |
| Diluted EPS | - | -188.96 | -68.72 | -11.26 | -1.70 |
| R&D Expense | 1.72M | 2.83M | 3.16M | 2.60M | 2.15M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 11.09M | 6.34M | 9.84M | 10.76M |
| Current Assets | - | - | 9.35M | 3.89M | 8.21M | 6.77M |
| Cash & Equivalents | - | - | 2.13M | 2.43M | 6.54M | 3.76M |
| Inventory | - | - | 415.00K | 554.00K | 606.00K | 1.05M |
| Receivables | - | - | 228.00K | 518.00K | 863.00K | 1.70M |
| Total Liabilities | - | - | 4.84M | 5.57M | 3.87M | 5.72M |
| Current Liabilities | - | - | 2.53M | 3.14M | 1.87M | 3.21M |
| Long Term Debt | - | - | - | - | - | - |
| Total Debt | - | - | 911.00K | 1.86M | 428.00K | 141.00K |
| Total Equity | -2.71M | - | 6.25M | 778.00K | 5.97M | 5.04M |
| Shares Outstanding | - | - | 140.46K | 325.04K | 3.14M | 10.85M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -12.03M | -12.18M | -9.88M | -10.74M |
| Investing Cash Flow | - | -2.88M | 6.14M | -186.00K | -1.02M |
| Financing Cash Flow | - | 14.11M | 6.30M | 14.12M | 8.99M |
| Capital Expenditure | - | -847.00K | -361.00K | -186.00K | -273.00K |
| Free Cash Flow | - | -12.87M | -12.54M | -10.06M | -11.02M |
| Net Change in Cash | - | -795.00K | 261.00K | 4.06M | -2.78M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | -92.8% | 42.4% | 52.2% | 59.8% |
| Operating Margin % | - | -2,709.8% | -537.1% | -420.1% | -324.3% |
| Net Margin % | - | -2,737.6% | -532.1% | -417.2% | -318.4% |
| ROE % | - | -302.6% | -2,002.7% | -229.0% | -249.1% |
| ROCE % | - | -218.8% | -490.7% | -172.6% | -169.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Warberg Asset Management LLC | 1.19% | 12.30K | $50.17K |
| 2 | Armistice Capital, LLC | 0.48% | 4.92K | $20.06K |
| 3 | HRT Financial LP | 0.23% | 2.42K | $9.86K |
| 4 | Geode Capital Management, LLC | 0.22% | 2.30K | $9.39K |
| 5 | Vanguard Capital Management LLC | 0.20% | 2.05K | $8.36K |
| 6 | Vanguard Fiduciary Trust Co | 0.12% | 1.27K | $5.20K |
| 7 | SBI Securities Co., Ltd. | 0.11% | 1.14K | $4.63K |
| 8 | Northern Trust Corporation | 0.09% | 887 | $3.62K |
| 9 | Spectrum Asset Management, Inc. (NB/CA) | 0.03% | 304 | $1.24K |
| 10 | Citigroup Inc. | - | 49 | $199 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TNON
$TNON stock is down 12% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNeHp2TUc1MTBrNE1xMVVIemFtcXpGdHFoQ1hyakRUWlRDa2pYc216OUlrYm1oemRpWE9adnZ1YXBPbEJQVXhLZjNIUGE1aWtqYjIxUHdJVXZJb0gyMThpTGRoWmxpcjBmV1pUX1lOV2dPTG5nUkV6clRlel8yNDRfU3ZwOE5raEttSGk2QX…
Tenon Medical (TNON) completes private raise in exempt deal - Stock Titan
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPR1hIbUpDWGI4U3VicXp5bXFNRDZudEpjVEdyaFQ1RGRiY1BPZFJ2Y2xKNHBPVTNZYnhCbFZQeWp0cTRSZ2dMX3djQmxhVEhOT3ZweHptN2xSV1BBY0xJa0ZleU1HNmprRGlFLWdSdFZvblNJVDVTS0Vkbmt3cVotclhpZHRNdGRNaWV3dG…
Tenon Medical, Inc. Announces 1:35 Reverse Stock Split - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNOE5XOXZtc3lBTDFtSExDdkt1QjlEa05VSGhoTmMyTmpIcjFaZVpNTnpDaHlDOTU4cWEzVVRFZUs1MmpxNDlNR2pOQ2JlRmFpUm9UQmtUYkRBQWVvRTZ3SEM2OXV3amFPeWkzS3RhRVd1NzEtQXZFNHNGakdhQ2NUNjFLZWZxT0Q2cHF4Y2…
Tenon Medical Stock Climbs Friday: What's Going On? - Benzinga
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxOSEZ3bGQzRW1JVXpMTlEwN3hCQVIzakJyOVByQWkwVkRJS2ZOQUZXdnF1YnVQb1VrS2dkV2IybWxnY2lDVUYzVDUzbE9CNk1uaU1SV1U5cEpnS2MwUUJVV016dmItMEJHaXREUUNqRkdNUkw1R0pTTk44SWZFV0hyTktmcWFkTjI1RFlmdG…
TNON Stock Whipsaws As Growth Collides With Risk - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9QTXNvQUdMNUJxNmQ3VEpJZFlGWTFvXzNoLUhpdS1LWWJleEg4UkNYdHpYVElEZ29KQVNFbnhXWVBHalYxdGtmY3o4U3NBRkFVYU11QjlYakV2RUxXZjRFaHBGZUtVSkwtZWtRRFUwRTh1SFVscHJpTy1B?oc=5" target="_blank">TNO…
Tenon Medical (TNON) Stock Jumps Nearly 83% After Hours: Here's What Is Going On - Sahm
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNTVBIOG8xOVplLUphVzgxN3VTOVA4c3B5cGxnMVlzTVR5WDhiWk9HeDFKWTdOYXpHTkg3R3J3N2ZvN3ZpQkhvWGJZeE15UW9EMVBRTVVUSjBBOTRfN2RzaEs4UUdKZno5eTMyTkkySW9zT0xXZTB4TGNIRHFmQzdySkQwSkp6bWtnczFISk…
TNON — Frequently Asked Questions
What is the current share price of Tenon Medical, Inc. (TNON)?
As of 2026-09-19 21:16 PDT, Tenon Medical, Inc. (TNON) trades at $3.36 on NasdaqCM. Its 52-week range is $1.15 to $45.15.
What is the market capitalisation of TNON?
Tenon Medical, Inc. (TNON) has a market capitalisation of $2.24M on NasdaqCM.
What is the P/E ratio of TNON?
TNON trades at a trailing price-to-earnings (P/E) ratio of -0.08. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.28.
Is TNON a good stock to buy?
This page provides a data-driven analysis of Tenon Medical, Inc. (TNON), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.